Notch signaling pathway as a therapeutic target in breast cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 1, 2011, Pages 9-15

  Al Hussaini, Hamed ^a   Subramanyam, Deepa ^b   Reedijk, Michael ^a   Sridhar, Srikala S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; ADAM PROTEIN INHIBITOR; ANTIESTROGEN; BEVACIZUMAB; DOCETAXEL; GAMMA SECRETASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; LETROZOLE; MK 0752; NOTCH RECEPTOR; PROTEIN INHIBITOR; PROTEIN KINASE B; RO 4929097; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ABDOMINAL CRAMP; ADVANCED CANCER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG TARGETING; EARLY CANCER; FATIGUE; HUMAN; HYPOPHOSPHATEMIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 78751557260     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0677     Document Type: Review

References (83)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004;131:965-73.
3. Muskavitch MA. Delta-notch signaling and Drosophila cell fate choice. Dev Biol 1994;166:415-30.
4. Radtke F, Raj K. The role of notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67.
5. Pintar A, De Biasio A, Popovic M, Ivanova N, Pongor S. The intracellular region of Notch ligands: does the tail make the difference? Biol Direct 2007;2:19.
6. Moloney DJ, Panin VM, Johnston SH, et al. Fringe is a glycosyltransferase that modifies Notch. Nature 2000;406:369-75.
7. Zhang YW, Luo WJ, Wang H, et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. J Biol Chem 2005;280:17020-6.
8. Fortini ME, Artavanis-Tsakonas S. Notch: neurogenesis is only part of the picture. Cell 1993;75:1245-7.
9. Jarriault S, Brou C, Logeat F, et al. Signalling downstreamof activated mammalian Notch. Nature 1995;377:355-8.
10. Hsieh JJ, Henkel T, Salmon P, et al. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996;16:952-9.
11. Kopan R, Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 2000;14:2799-806.
12. Zhou S, Fujimuro M, Hsieh JJ, et al. SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC to facilitate NotchIC function. Mol Cell Biol 2000;2400-10.
13. Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002;22:7688-700.
14. Kopan R. Notch: a membrane-bound transcription factor. J Cell Sci 2002;115:1095-7.
15. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001;21:5925-34.
16. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096-109.
17. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998;18:2077-88. (Pubitemid 28152657)
18. Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999;18:5973-81.
19. Chen Y, Fischer WH, Gill GN. Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. J Biol Chem 1997;272:14110-4.
20. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225-32.
21. Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserved domains to powerful functions. Curr Top Microbiol Immunol 1998;228:273-324.
22. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61.
23. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
24. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A 1995;92:6414-8.
25. Leethanakul C, Patel V, Gillespie J, et al. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene 2000;19:3220-4.
26. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006;66:6312-8.
27. Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483-93.
28. Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene 1997;14:1883-90. (Pubitemid 27217801)
29. Imatani A, Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000;19:223-31.
30. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25.
31. Yamaguchi N, Oyama T, Ito E, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008;68:1881-8.
32. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
33. Dickson BC, Mulligan AM, Zhang H, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007;20:685-93.
34. Reedijk M, Pinnaduwage D, Dickson BC, et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph nodenegative breast cancer. Breast Cancer Res Treat 2008;111:439-48.
35. Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21. (Pubitemid 39435065)
36. Rizzo P, Miao H, D'Souza G, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008;68:5226-35.
37. Osipo C, Patel P, Rizzo P, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008;27:5019-32.
38. Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23.
39. Funahashi Y, Shawber CJ, Vorontchikhina M, et al. Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res 2010;2:3.
40. Shawber CJ, Funahashi Y, Francisco E, et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 2007;117:3369-82.
41. Taylor KL, Henderson AM, Hughes CC. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res 2002;64:372-83.
42. Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006;12:4836-44.
43. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
44. Kesisis G, Touplikiotiy P, Yiannaki E, et al. Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer. American Society of Clinical Oncology 2010 Annual Meeting: Abstract 1134.
45. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4:677-85.
46. Mittal S, Subramanyam D, Dey D, Kumar RV, Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 2009;8:128.
47. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86.
48. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000;19:4191-8.
49. Liao WR, Hsieh RH, Hsu KW, et al. The CBF1-independent Notch1 signal pathway activates human c-myc expression partially via transcription factor YY1. Carcinogenesis 2007;28:1867-76.
50. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-24.
51. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
52. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
53. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
54. Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605-15.
55. Farnie G, Clarke RB, Spence K, et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007;99:616-27.
56. Sansone P, Storci G, Giovannini C, et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007;25:807-15.
57. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002.
58. Bane AL, Pinnaduwage D, Colby S, et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2009; 117:183-91.
59. Lee CW, Simin K, Liu Q, et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008;10:R97.
60. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003;22:6598-608.
61. Miele L, Miao H, Nickoloff BJ. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 2006;6:313-23.
62. Paris D, Quadros A, Patel N, et al. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol 2005;S14:1-15.
63. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
64. Lewis HD, Leveridge M, Strack PR, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007;14: 209-19.
65. Nickoloff BJ, Hendrix MJ, Pollock PM, et al. Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 2005;10: 95-104.
66. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
67. Luraguiz N. Targeting notch signalling and estrogen receptor pathways in human breast cancer stem cells. American Society of Clinical Oncology Annual Meeting 2008: Abstract 22066.
68. Rasul S, Balasubramanian R, Filipovic A, et al. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009;100:1879-88.
69. Efferson CL, Winkelmann CT, Ware C, et al. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 2010;70:2476-84.
70. Chi A. The additive effects of gamma secretase inhibitor and ionizing radiation in MDA-MD-231 breast cancer cell line. American Society of Clinical Oncology Annual Meeting 2008: Abstract 14594.
71. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052-7.
72. Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-31.
73. Krop I. Phase 1 pharmacokinetic (PK), and phrmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. American Society of Clinical Oncology 2006 Annual Meeting: Abstract 10574.
74. Merck. A Notch Signalling Pathway Inhibitor for Patients with Advanced Breast Cancer (0752-014). Clinical Trialsgov [Internet] Bethesda, MD: National Library of Medicine, 2000. Available from: http//clinicaltrials.gov/show/ NCT00106145.
75. University L. Study of MK-0752 in combination with tamoxifen or letrozole to Treat Early Stage Breast Cancer. Clinical Trialsgov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. Available from: http//clinicaltrials.gov/show/NCT00756717.
76. Center UoM. Phase I/II study of MK-0752 followed by Docetaxel in Advanced Metastatic Breast Cancer. Clinical Trials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. Available from: http://clinicaltrials. gov/show/NCT00645333.
77. Tolcher AW, Mikulski SM, W.A. M, et al. A phase I study of R04929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. In: American Society of Clinical Oncology Annual Meeting 2010: Abstract 2502.
78. Institute BAKC. GDC-0449 and R04929097 in Treating Women with Advanced Breast Cancer. Clinical Trialsgov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. Available from: http://clinicaltrials.gov/show/NCT01071564.
79. Lawson ND, Vogel AM, Weinstein BM. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 2002;3:127-36.
80. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005;7:86-95. (Pubitemid 40704127)
81. Bai F, Tagen M, Colotta C, et al. Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2348-52.
82. Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69: 7672-80.
83. Rominger CM, Bee WL, Copeland RA, et al. Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther 2009;329:995-1005.